Latest action: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Designates biotechnology and biomanufacturing as critical infrastructure requiring federal protection.
The problem
Biotechnology and biomanufacturing facilities may lack adequate security protections. The sector faces potential disruption from physical attacks, cyber threats, or other incidents that could harm national interests.
The proposal
The bill classifies biotech and biomanufacturing as critical infrastructure sectors. This triggers federal oversight, security standards, and coordination mechanisms to protect these facilities from threats.
The impact
Biotech companies, manufacturers, federal agencies, and workers are affected. Companies face new regulations. Agencies gain authority to oversee security. The sector receives protection from disruption.
Critical infrastructure designation provides federal resources and expertise to protect biotech facilities. This helps prevent potential attacks or sabotage that could disrupt important medical and industrial production.
Safeguarding biotech facilities protects a valuable sector that contributes jobs and medical innovation. Preventing disruptions protects companies' ability to operate and serve customers.
Protecting biomanufacturing ensures continued production of medicines, vaccines, and treatments. This helps maintain supply chains during crises or emergencies.
Strengthening biotech sector security helps the U.S. maintain leadership in biotechnology against international competition and threats.
Biotech companies must invest in new security measures and reporting systems to meet federal standards. Small companies may struggle more with these expenses than large corporations.
New federal oversight creates bureaucracy and paperwork requirements. Companies spend time on compliance instead of research and development.
Federal access to facility information and operations data raises questions about proprietary information protection. Companies worry about sharing trade secrets with government agencies.
Without specific standards defined in the bill, companies lack clarity on what is required. Agencies may interpret rules differently, creating inconsistent expectations.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.